The results of survival analysis showed that CCNL2 expression was related to the overall survival of BLCA, HNSC, KIRC, LGG and SARC patients and the progression-free survival of LGG and PRAD patients (Additional file 1: Figure S13). The gene discussed is CCNL2; the disease is prostate adenocarcinoma.